Case Report
Year 2017,
Volume: 1 Issue: 2, 72 - 74, 07.09.2017
Abstract
Alkol ve opioid bağımlılıkları tedavisinde ülkemizde yeni alternatifler arasında naltrekson cilt altı implant yer almaktadır. Bulantı, kusma, baş ağrısı, deri döküntüleri, depresyon, kaygı ve enerji kaybı naltrekson kullanımında bildirilen yan etkilerdir. Bu yazıda naltrekson cilt altı implant uygulaması sonrasında kaşıntı ve deri döküntüleri gelişen bir vaka tartışılacaktır.
Keywords
References
- 1. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-80.
- 2. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long acting injectable naltrexone for alcohol dependence: a randomized controlled trial. ]AMA 2005;293: 1617-25.
- 3. Johnson BA, Ait-Daoud N, Aubin H-J, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004; 28:1356-61.
- 4. Krupitsky EM, Blokhina EA.Long-acting depot formulations of naltrexone for heroin depedence: a review. Curr Opin Psychiatry. 2010; 23:210-4.
- 5. Şukru Balevi. İlac reaksiyonları. Genel Tıp Dergisi 1997; 7:209-15.
- 6. Boyvat, Ayşe. İlaç erüpsiyonlarında patogenez ve klinik özellikler. Turkiye Klinikleri Journal of Dermatology Special Topics, 2008, 1.1: 47-57.
- 7. Erkek E: Kutanoz İlac Reaksiyonları. in: Tuzun Y, Gurer MA, Serdaroğlu S,Oğuz O, Aksungur VL (editorler). Dermatoloji. 3. Baskı, İstanbul: Nobel Tıp Kitabevleri, 2008: 269-316.
- 8. Martin T, Hui L. Severe cutaneous adverse drug reactions: a review onepidemiology, etiology, clinical manifestation and pathogenesis. Chin Med J. 2008; 121: 756-61.5.
- 9. Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: anoverview. J Postgrad Med 1996; 42: 15-22.
- 10. Abboud TK, Afrasiabi A. Davidson JMD et al. Prophylactic oral naltrexone with epidural morphine: Effect on adverse reactions and ventilatorj' responses to carbon dioxide. Anesthesiology 1990; 72: 233-7.
- 11. Peer G, Kivity S, Agami O et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348: 1552-4.
- 12. Carson KL, Tran 'iT. Cotton P, Sharara Al, Hum CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Anı J Gastroenterol. 1996; 91: 1022-5.
- 13. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ. 1988; 297: 1501-4.
- 14. Bergasa NV, Vergalla J, Jones EA. Acute cholestasis in the rat induces mild analgesia; reversal by naloxone. Hepatology. 1990; 12:887.
- 15. Sullivan JR, Watson A. Naltrexone: a case report of pruritus from an antipruritic. Australas J Dermatol. 1997; 38:196-8.
Year 2017,
Volume: 1 Issue: 2, 72 - 74, 07.09.2017
Abstract
References
- 1. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-80.
- 2. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long acting injectable naltrexone for alcohol dependence: a randomized controlled trial. ]AMA 2005;293: 1617-25.
- 3. Johnson BA, Ait-Daoud N, Aubin H-J, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004; 28:1356-61.
- 4. Krupitsky EM, Blokhina EA.Long-acting depot formulations of naltrexone for heroin depedence: a review. Curr Opin Psychiatry. 2010; 23:210-4.
- 5. Şukru Balevi. İlac reaksiyonları. Genel Tıp Dergisi 1997; 7:209-15.
- 6. Boyvat, Ayşe. İlaç erüpsiyonlarında patogenez ve klinik özellikler. Turkiye Klinikleri Journal of Dermatology Special Topics, 2008, 1.1: 47-57.
- 7. Erkek E: Kutanoz İlac Reaksiyonları. in: Tuzun Y, Gurer MA, Serdaroğlu S,Oğuz O, Aksungur VL (editorler). Dermatoloji. 3. Baskı, İstanbul: Nobel Tıp Kitabevleri, 2008: 269-316.
- 8. Martin T, Hui L. Severe cutaneous adverse drug reactions: a review onepidemiology, etiology, clinical manifestation and pathogenesis. Chin Med J. 2008; 121: 756-61.5.
- 9. Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: anoverview. J Postgrad Med 1996; 42: 15-22.
- 10. Abboud TK, Afrasiabi A. Davidson JMD et al. Prophylactic oral naltrexone with epidural morphine: Effect on adverse reactions and ventilatorj' responses to carbon dioxide. Anesthesiology 1990; 72: 233-7.
- 11. Peer G, Kivity S, Agami O et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348: 1552-4.
- 12. Carson KL, Tran 'iT. Cotton P, Sharara Al, Hum CM. Pilot study of the use of naltrexone to treat the severe pruritus of cholestatic liver disease. Anı J Gastroenterol. 1996; 91: 1022-5.
- 13. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. BMJ. 1988; 297: 1501-4.
- 14. Bergasa NV, Vergalla J, Jones EA. Acute cholestasis in the rat induces mild analgesia; reversal by naloxone. Hepatology. 1990; 12:887.
- 15. Sullivan JR, Watson A. Naltrexone: a case report of pruritus from an antipruritic. Australas J Dermatol. 1997; 38:196-8.
There are 15 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Psychology, Subtance Abuse |
| Journal Section | Case Reports |
| Authors | |
| Publication Date | September 7, 2017 |
| Published in Issue | Year 2017 Volume: 1 Issue: 2 |
